Advances on Albumin‐Based Carriers for Anticancer Drug Delivery

Albumin is the most abundant protein in plasma, featuring a unique chemical structure and conformation that underpins its functions. Its excellent biocompatibility, nontoxicity and non‐immunogenicity make it an ideal carrier for encapsulating therapeutic agents, particularly in controlled release applications for cancer treatment. Although existing reviews focus on albumin‐based particulate delivery systems, there is a lack of comprehensive analysis from the perspective of using albumin's structural characteristics and binding sites for drug delivery. This review categorizes albumin's drug‐loading modes based on its surface‐active groups and internal binding sites, emphasizing drug‐loading strategies and targeting mechanisms. It also details the preparation and modification methods for albumin nanoparticles, along with clinical performance evaluations. Finally, it addresses current challenges and proposes potential solutions. This review aims to provide valuable insights for developing advanced albumin‐based anticancer drugs with enhanced therapeutic efficacy.